Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

NCT05999604 | Recruiting Phase 3 DMC

• 1 other identifier: CBR_2022_13
• Study Type: interventional
• Target: 244
• Locations: 1 country
• Sites: 11

Brief Summary

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and the leading cause of severe non-traumatic disability in young people, affecting 110,000 people in France. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, has shown remarkable efficacy in Phase III trials on the inflammatory component of the disease, reducing the annualized relapse rate by 46% and the rate of new T2 lesions by 80% compared with interferon-β 1a. The use of anti-CD20 agents, including ocrelizumab, is associated with an infectious risk that increases with duration of exposure, part of which is due to the development of hypo-gammaglobulinemia in relation to cumulative dose. Several reports suggest a persistent effect of anti-CD20 drugs in MS, with no resumption of inflammatory activity after discontinuation:

• During the development of ocrelizumab, at the end of phase 2, after having received 3 or 4 semi-annual cycles of ocrelizumab, a safety period with a therapeutic window of 18 months was planned, before re-administration in the extension study. During this therapeutic window, the annualized relapse rate remained stable, and patients showed no radiological disease activity.
• Scandinavian observational studies of "off-label" use of anti-CD20 in MS provide real-life evidence of the absence of recovery of clinical and radiological activity after prolonged interruption of treatment. After 2 years of treatment, and with disease activity under control, spacing administration intervals could reduce the risk of infection without reducing treatment efficacy. This would facilitate the decision to maintain highly active immunotherapy over the long term. In addition, this therapeutic de-escalation, by reducing the frequency of infusions and associated day hospitalizations, would help to reduce treatment management costs. Our aim is to evaluate the non-inferiority of 12-monthly spacing of ocrelizumab infusions versus the conventional 6-monthly regimen, in a population of active MS patients over 18 years of age who have already received 4 or more semi-annual cycles of treatment for 2 years.

Conditions

Multiple Sclerosis

Outcome Measures

Primary Outcomes (1)

• Absence of radiological disease activity at 2 years

  Percentage of patients with no new or enlarged T2 lesion \>3mm on cerebrospinal MRI at 24 months compared with inclusion MRI. MRI readings at inclusion and M24 will be performed by an independent radiologist blinded to the treatment arm.

  Months24

Study Arms (2)

annual ocrelizumab infusions

EXPERIMENTAL

Drug: Ocrelizumab Injection [Ocrevus]

semestrial ocrelizumab infusions

OTHER

Drug: Ocrelizumab Injection [Ocrevus]

Interventions

Ocrelizumab Injection [Ocrevus] DRUG

Semestrial administration

semestrial ocrelizumab infusions

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient 18 years of age or older
• Presenting for a 4th semi-annual cycle of ocrelizumab (minimum)
• Requires follow-up MRI as part of treatment.
• Initial indication for ocrelizumab according to the marketing authorization (active MS, RR or SP form)
• Absence of relapse for at least 18 months (a relapse being defined as the appearance of new symptoms or worsening of existing symptoms, lasting more than 24 hours and outside a period of fever or an infectious episode; notified as a validated relapse by the neurologist in the patient's file, treated or not with boluses of Solu-Medrol).
• EDSS between 0 and 6 inclusive
• Having received informed information about the study and having signed a consent to participate in the study
• French language proficiency
• Affiliated or beneficiary of a social insurance scheme

You may not qualify if:

• Clinical forms of primary progressive MS
• Patients already receiving systematically spaced doses of ocrelizumab ≥ 9 months apart
• Contraindication to continued treatment with ocrelizumab (hypersensitivity reaction, ongoing active infection, development of malignancy since previous injection, development of severe immune deficiency)
• Planned pregnancy within 3 years
• Contraindication to MRI
• Contraindication to injection of contrast media
• Subject with severe or uncontrolled symptoms of renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric or cardiac disease, or any uncontrolled intercurrent pathology.
• Patient under legal protection
• Patients of childbearing age who do not wish to use effective contraception
• Pregnant or breast-feeding women

Sponsors & Collaborators

• Fondation Ophtalmologique Adolphe de Rothschild: lead

Study Sites (11)

Hôpital Henri Mondor

Créteil, 94010, France

RECRUITING

CH Gonesse

Gonesse, 95500, France

RECRUITING

CHU de Grenoble

Grenoble, 38043, France

RECRUITING

CHU de Limoges

Limoges, 87042, France

RECRUITING

Hôpital Pierre Wertheimer (HCL)

Lyon, 69500, France

RECRUITING

CHU de Nice

Nice, 06000, France

RECRUITING

Hôpital de la Pitié-Salpêtrière

Paris, 75013, France

RECRUITING

Fondation Adolphe de Rothschild

Paris, 75019, France

RECRUITING

CHI Poissy-Saint-Germain en Laye

Poissy, 78300, France

RECRUITING

CHU de Strasbourg

Strasbourg, 67098, France

RECRUITING

Hôpital Foch

Suresnes, 92150, France

RECRUITING

MeSH Terms

Conditions

Multiple Sclerosis

Interventions

ocrelizumab

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

Dr Caroline Bensa

CONTACT

+33 148036753; cbensa@for.paris

Dr Amélie Yavchitz

CONTACT

ayavchitz@for.paris

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 11, 2023
• First Posted: August 21, 2023
• Study Start: November 9, 2023
• Primary Completion (Estimated): November 1, 2029
• Study Completion (Estimated): November 1, 2029
• Last Updated: January 21, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

FR (11)